Biotech Startups

Gut microbiome mapping for better medicines

1 investor

Praxis Packaging provides contract manufacturing services for pharmaceutical products, including solid dose bottling, blister packaging, liquid/cream/paste filling, and secondary packaging solutions for both prescription and over-the-counter medications in FDA and cGMP-compliant facilities.

1 investor

Therapeutic company focused on validated targets for treating neurological and psychiatric disorders.

1 investor

Prazer Therapeutics develops therapeutics using Targeted Protein Degradation (TPD) technology, including its SPiDEM platform, in which small molecules selectively bind pathological proteins and activate the ubiquitin-proteasome system for their elimination. The company's pipeline focuses on treatments for viral infections and associated diseases as well as other refractory conditions.

1 investor

PRCXI manufactures laboratory equipment including oscillating incubators, shakers, and magnetic stirrers for scientific and research applications.

1 investor

PRD Therapeutics is a drug-discovery startup developing first-in-class oral SOAT2-selective inhibitors (PRD compounds derived from pyripyropene A) to regulate lipid metabolism. Its lead program targets the rare disease homozygous familial hypercholesterolemia (HoFH), with planned expansion to MASH/MASLD and other lipid-metabolism disorders.

1 investor

Nutrumami develops multifunctional food ingredients made from fermented faba protein (faba beans, oats, sea salt) using solid-state fermentation, delivering taste, texture, and nutrition while reducing additives and animal ingredients. Its FermiPro product line targets food manufacturers making ready meals, plant-based cheese, hybrid meat products, sauces, and snacks, and it offers co-development and waste-stream valorization services.

1 investor

Precise Bio is a regenerative medicine company that develops bio-printed tissues and organs using a 4D bio-fabrication platform, initially focused on ophthalmology including a fabricated human cornea program. It serves patients with unmet medical needs that cannot be met with donor tissue, with facilities in North Carolina, USA and Shoham, Israel.

1 investor

PrecisionBiotics develops food supplements containing specific bacterial strains aimed at supporting gut health and the microbiome for consumers and clinicians, alongside educational resources on gut health. The company originated from microbiome research with the APC Microbiome Institute at UCC in Ireland and is now part of the Novonesis Group.

1 investor

Precision Chroma develops 3D-printed chromatography columns using patented technology for laboratory and analytical applications. The company is a spinoff from the University of Canterbury focused on next-generation separation and analysis equipment for the chemical and life sciences industries.

1 investor

Precision Cell Systems is a company that provides products and services related to genomics and cell/biology research, offering resources, webinars, and product ordering through its website. The available page is a privacy policy and does not describe the specific products in detail.

1 investor

PrecisionLife uses advanced AI and analytics to identify the biological mechanisms underlying complex chronic diseases, enabling earlier diagnosis and more personalized treatment selection. The company develops diagnostic tests, clinical tools, and insights for pharmaceutical and healthcare partners to improve disease understanding and patient outcomes across multiple therapeutic areas.

1 investor

PrecisionPhage develops computational and laboratory solutions for bacteriophage research to address antimicrobial resistance. The company creates bioinformatics tools and phage-based technologies intended for healthcare and biotech applications globally.

1 investor

Predicta Biosciences operates a molecular insights platform for blood cancer care, using whole genome sequencing of intact circulating tumor cells from a single blood sample combined with single-cell immune profiling to characterize disease biology and immune response. Its diagnostics serve clinicians, researchers, and pharmaceutical partners working in hematological malignancies such as multiple myeloma.

1 investor

Predictiv Care uses DNA and genomic analysis to identify genetic predispositions so diseases can be predicted and prevented, with a focus on personalized, preventive health. The company aims to make precision and preventive healthcare affordable and understandable for individuals.

1 investor

DrugPatentWatch provides biopharmaceutical intelligence drawn from primary sources such as the USPTO, FDA Orange Book, ANDA filings, litigation records, and patent registers across 134 countries, covering drug patents, pipelines, litigation, and pricing. It serves pharmaceutical professionals including generics manufacturers, biotech firms, and distributors, offering continuously updated, exportable data for competitive and market analysis.

1 investor

PredictXBio uses AI, machine learning, and bioinformatics pipelines to predict how pathogens respond to drugs and to model antimicrobial potency in silico, aiming to accelerate discovery of antimicrobials against antimicrobial resistance. Its tools serve drug developers by predicting future resistance mutations and testing therapeutic compounds computationally.

1 investor

PreGen applies artificial intelligence to gene expression data to develop clinically validated prognostic and predictive molecular tests for cancer patients, starting with prostate cancer. Its tests run on standard PCR equipment with results delivered via a web platform, designed for decentralized deployment in emerging countries, with a focus on Latin America.

1 investor

Premark Pharma develops therapeutic candidates for ophthalmologic conditions including blepharitis and dry eye disease. The company is advancing clinical-stage programs through Phase 3 development.

1 investor

A healthcare-focused company spun out from Hamamatsu University School of Medicine that aims to develop disease treatments and save patients' lives through scientific innovation. The company also contributes to disaster preparedness and emergency medical response in the Hamamatsu region.

1 investor

Presentient develops BRAKES, a data science platform that analyzes clinical trial data using automation in secure enclaves to maintain blinding while enabling interim analyses, potentially reducing trial duration by up to 50% and identifying failing trials early.

1 investor

PreView Medical develops AI-powered spectroscopy systems for prostate cancer detection and treatment. The company has created the ClariCore® Biopsy System to improve detection during biopsies and a focal therapy system for precise treatment of prostate cancer.

1 investor

Esopredict is a methylation-based risk-stratification test that quantifies DNA methylation of four genes (p16, RUNX3, HPP1, FBN1) combined with patient age to predict a patient's 5-year risk of progressing from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma. Offered by Castle as a companion to its TissueCypher test, it produces a risk score and risk level to help clinicians manage patients with non-dysplastic, indefinite, or low-grade Barrett's esophagus.

1 investor

PRIMACYT develops isolated liver cell models and toxicity testing services for medical device and pharmaceutical research. The company serves research institutions, universities, and industrial clients requiring preclinical safety assessment capabilities.

1 investor